2806125-84-6
Chemical Structure
Sarcosine-13C3
Synonym(s): N-Methylglycine-13C3; Sarcosin-13C3
- CAS No.: 2806125-84-6
- Formula:13C3H7NO2
- Molecular Weight:92.07
IUPAC Name: (methyl-13C)glycine-13C2
InChIKey: FSYKKLYZXJSNPZ-VMIGTVKRSA-N
SMILES: O[13C]([13C]([H])(N[13CH3])[H])=O
Biological Activity: Sarcosine-13C3 (N-Methylglycine-13C3; Sarcosin-13C3) is the 13C-labeled Sarcosine (HY-101037). Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sarcosine-13C3 | Sarcosine-13C3 (N-Methylglycine-13C3; Sarcosin-13C3) is the 13C-labeled Sarcosine (HY-101037). Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sarcosine (Standard) | 99.93% | Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sarcosine-d3 | 99.05% | Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sarcosine-15N | 99.92% | Sarcosine-15N is the 15N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sarcosine | 98.0% | Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Katarzyna Socała, et al. Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models. Pharmacol Rep. Mar-Apr 2010;62(2):392-7. [Content Brief]
- [2]. Mei-Yi Lee, et al. Effects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials. J Biomed Sci. 2017; 24: 18. [Content Brief]
